ICLE 2022 | Targeting public neoantigens in cancer immunotherapies
Unlike private neoantigens, which are unique to patients and typically arise from passenger mutations, public neoantigens are found in multiple patients. Chris Klebanoff, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the advantages of targeting public neoantigens in the development of cell therapies for cancer. Private neoantigens tend to not be directly important in the proliferation of cancer and hence are low-value targets, whereas public neoantigens tend to arise from the mutation of commonly expressed oncogenes such as PI3K, KRAS and p53. Therapies targeting public neoantigens will consequently be lower to produce as they will be more commonly found in patients. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
